New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
- PMID: 33256747
- PMCID: PMC7703505
- DOI: 10.1186/s12954-020-00448-2
New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries
Abstract
Background: This study examines the use of new psychoactive substances (NPS) and the harm reduction response in six Eurasian countries: Belarus, Moldova, Serbia, Kazakhstan, Kyrgyzstan, and Georgia. The aim is to identify current patterns of NPS use and related harms in each country through recording the perspectives and lived experience of people who use drugs and people who provide harm reduction services in order to inform the harm reduction response.
Methodology: The study involved desk-based research and semi-structured interviews/focus groups with 124 people who use drugs and 55 health and harm reduction service providers across the six countries.
Results: People who use drugs in all countries were aware of NPS, primarily synthetic cathinones and synthetic cannabinoids. NPS users generally reflected two groups: those with no prior history of illicit drug use (typically younger people) and those who used NPS on an occasional or regular basis due to the lack of availability of their preferred drug (primarily opiates). In many cases, these respondents reported they would not use NPS if traditional opiates were available. Common factors for choosing NPS included cost and accessibility. Respondents in most countries described NPS markets that use the DarkNet and social media for communication, secretive methods of payment and hidden collection points. A recurring theme was the role of punitive drug policies in driving NPS use and related harms. Respondents in all countries agreed that current harm reduction services were important but needed to be enhanced and expanded in the context of NPS.
Conclusions: The study identified patterns and drivers of NPS use, risk behaviours and drug-related harms. It identified gaps in the current harm reduction response, particularly the needs of non-injectors and overdose response, as well as the harmful effects of punitive drug policies. These findings may inform and improve current harm reduction services to meet the needs of people who use NPS.
Keywords: Belarus; Eurasia; Georgia; Harm reduction; Kazakhstan; Kyrgyzstan; Moldova; NPS; New psychoactive substances; Serbia.
Conflict of interest statement
There are no competing interests to declare for the authors.
Similar articles
-
What is needed for implementing drug checking services in the context of the overdose crisis? A qualitative study to explore perspectives of potential service users.Harm Reduct J. 2020 May 12;17(1):29. doi: 10.1186/s12954-020-00373-4. Harm Reduct J. 2020. PMID: 32398090 Free PMC article.
-
New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe.Int J Drug Policy. 2017 Feb;40:84-92. doi: 10.1016/j.drugpo.2016.10.004. Epub 2016 Dec 9. Int J Drug Policy. 2017. PMID: 27956184
-
New Psychoactive Substances and receding COVID-19 pandemic: really going back to "normal"?Acta Biomed. 2022 May 11;93(2):e2022186. doi: 10.23750/abm.v93i2.13008. Acta Biomed. 2022. PMID: 35545997 Free PMC article.
-
New psychoactive substances in Australia: patterns and characteristics of use, adverse effects, and interventions to reduce harm.Curr Opin Psychiatry. 2020 Jul;33(4):343-351. doi: 10.1097/YCO.0000000000000606. Curr Opin Psychiatry. 2020. PMID: 32250983 Review.
-
[The challenges for psychiatric care posed by synthetic drugs].Nervenarzt. 2024 Sep;95(9):818-823. doi: 10.1007/s00115-024-01705-6. Epub 2024 Aug 26. Nervenarzt. 2024. PMID: 39186107 Review. German.
Cited by
-
Phytocannabinoids: Pharmacological effects, biomedical applications, and worldwide prospection.J Tradit Complement Med. 2023 Aug 26;13(6):575-587. doi: 10.1016/j.jtcme.2023.08.006. eCollection 2023 Nov. J Tradit Complement Med. 2023. PMID: 38020546 Free PMC article. Review.
-
Automating Detection of Drug-Related Harms on Social Media: Machine Learning Framework.J Med Internet Res. 2023 Sep 19;25:e43630. doi: 10.2196/43630. J Med Internet Res. 2023. PMID: 37725410 Free PMC article.
-
Synthetic cannabinoids awareness among patients with opioid use disorder in Serbia - A survey based cross-sectional pilot study.Front Psychiatry. 2023 Mar 7;14:987726. doi: 10.3389/fpsyt.2023.987726. eCollection 2023. Front Psychiatry. 2023. PMID: 36960457 Free PMC article.
-
Perceived risk and condomless sex practice with commercial and non-commercial sexual partners of male migrant sex workers in London, UK.F1000Res. 2023 Oct 19;10:1033. doi: 10.12688/f1000research.73248.2. eCollection 2021. F1000Res. 2023. PMID: 37928318 Free PMC article.
-
New Psychoactive Substances: Awareness and Attitudes of Future Health Care Professionals in Serbia.Int J Environ Res Public Health. 2022 Nov 11;19(22):14877. doi: 10.3390/ijerph192214877. Int J Environ Res Public Health. 2022. PMID: 36429596 Free PMC article.
References
-
- United Nations Office on Drugs and Crime. The challenge of new psychoactive substances. United Nations Office on Drugs and Crime. 2013.
-
- Evans-Brown M, Gallegos A, Francis W, Christie R, Cunningham A, Sekula J, et al. New psychoactive substances in Europe an update from the EU Early Warning System, March 2015. European Monitoring Centre on Drugs and Drug Addiction. 2016.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical